Women with PMOS should get subsidised weight-loss drugs, Australian advocates say

Symptoms of polyendrocrine metabolic ovarian syndrome include weight gain, hair loss and irregular periods. Photograph: James Manning/PA

Women living with a chronic hormonal condition should have access to taxpayer-funded weight-loss medications, advocates say.

The Polyendrocrine Metabolic Ovarian Syndrome Association of Australia (POSAA) is urging for GLP-1 drugs to be approved on the Pharmaceutical Benefits Scheme for people living with the condition.